Remodeling valves in a 13.5-day-old embryonic mouse heart.
Credit: Lauren Goddard, PhD, Perelman School of Medicine, University of Pennsylvania
PHILADELPHIA — Congenital heart valve defects appear in 2 percent of all live births, making them the most common type of birth defect. While some of these defects have been linked to specific genetic mutations, the majority have no clearly definable genetic cause, suggesting that epigenetic factors – changes in gene expression versus an alteration in the genetic code -- play an important role. Now researchers from the Perelman School of Medicine at the University of Pennsylvania have found that the force, or shear, of blood flow against the cells lining the early heart valve sends signals for heart “cushion” cells to become fully formed valves. Their findings are published in Developmental Cell.
Heart valves ensure that the beating heart drives blood flow in one direction. As the heart beats continuously over a lifetime, valve function must be flawless. Obstruction of forward flow or backward flow due to a defective valve can result in heart failure. Most serious valve defects are treated surgically, with the original valve able to be repaired and or replaced. However, in general, valve replacements are held off in growing children for as long as possible to avoid outgrowing a valve replaced too early.
Embryonic heart valves develop as large cushions that, during development, reshape and thin to form mature valve leaflets. “The maturation of these big fluffy cushions into the perfectly fitting leaflets of a mature heart valve is an architectural marvel,” said senior author Mark Kahn, MD, a professor of Cardiovascular Medicine. “We showed that shear-responsive KLF2-Wnt protein signaling is the basis of this remodeling.”
Lauren Goddard, PhD, a postdoctoral researcher in the Kahn Lab, found that the protein KLF2 was expressed by the shear-sensing cells that line the primitive valve cushions. KLF2’s expression was highest in the regions of the valve that experience the strongest shear forces. Using mouse models, she found that deletion of KLF2 in these cells resulted in large cushions that failed to mature properly. Profiling of the genes expressed by early cardiac cushion cells revealed that loss of KLF2 resulted in a significant decrease in the expression of the Wnt binding partner, WNT9B, a molecule important in the valve maturation communication path.
Loss of WNT9B in the mouse resulted in defective valve remodeling similar to what happens when KLF2 is deleted, suggesting it is a key downstream target of KLF2. Work done by co-author Julien Vermot from the Agence Nationale de la Recherche, an expert in how shear forces determine zebrafish development, demonstrated that expression of the gene for WNT9B is restricted to the cells that govern developing heart valves and is dependent on the shear force of early blood flow. These findings were instrumental in linking shear forces to KLF2-WNT9B signaling during valve remodeling.
This work is the first to demonstrate how blood flow shapes developing heart valves into mature valve leaflets. These studies, say the researchers, predict that even a minor breakdown in the series of precisely orchestrated cell-cell communications required to accurately pass on signals from blood flow may result in subtly defective valves. This idea supports an epigenetic explanation for common congenital valve defects.
The research was supported by the National Institutes of Health (R01HL094326, T32HL007954, R0111770, R01116997), the Agence Nationale de la Recherche, and the European Research Council.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.